COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00039520
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : May 6, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fox Chase Cancer Center

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining sulindac with docetaxel in treating women who have metastatic or recurrent breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: docetaxel Drug: sulindac Phase 2

Detailed Description:


  • Determine the response rate of women with metastatic or recurrent adenocarcinoma of the breast treated with sulindac and docetaxel.
  • Determine the time to progression of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive oral sulindac twice daily. Patients also receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed within 3-4 weeks.

PROJECTED ACCRUAL: Approximately 12-33 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast
Study Start Date : January 2002
Actual Primary Completion Date : June 2004
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the breast

    • Metastatic or recurrent disease
  • Measurable disease

    • Bone only disease is not eligible
  • No hematologic malignancy
  • No carcinomatous meningitis and/or untreated or uncontrolled brain parenchymal disease

    • At least 8 weeks since prior therapy for brain parenchymal disease and patient must be asymptomatic from CNS disease
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status:

  • Premenopausal or postmenopausal

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than upper limit of normal (ULN)
  • One of the following:

    • SGOT and SGPT no greater than 2.5 times ULN AND
    • Alkaline phosphatase no greater than ULN OR
    • SGOT and SGPT no greater than ULN AND
    • Alkaline phosphatase no greater than 4 times ULN


  • Creatinine no greater than 2.0 mg/dL


  • No unstable angina
  • No uncontrolled atrial or ventricular arrhythmias
  • No congestive heart failure
  • No uncontrolled hypertension


  • No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer
  • No active unresolved infection
  • No poorly controlled diabetes mellitus
  • No prior hypersensitivity reactions to sulindac or Polysorbate 80
  • No peripheral neuropathy grade 2 or greater
  • No active peptic ulcer disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • At least 4 weeks since prior immunotherapy
  • No concurrent biological response modifiers
  • No concurrent trastuzumab (Herceptin)


  • No more than 1 prior chemotherapy regimen in the adjuvant setting
  • No more than 1 prior chemotherapy regimen for recurrent or metastatic disease
  • No prior docetaxel
  • Prior paclitaxel allowed
  • At least 1 week since prior chronic sulindac
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No other concurrent sulindac
  • No other concurrent chemotherapy

Endocrine therapy:

  • Not specified


  • At least 4 weeks since prior radiotherapy
  • No prior radiotherapy to more than 25% of bone marrow
  • No concurrent radiotherapy


  • Not specified


  • At least 1 week since prior antibiotics
  • At least 4 weeks since prior investigational agents
  • No other concurrent investigational drugs
  • No other concurrent antineoplastic therapy
  • No concurrent chronic (full dose for more than 2 weeks) nonsteroidal anti-inflammatory drugs (except ibuprofen or naproxen sodium), including cyclo-oxygenase-2 inhibitors and salicylates (e.g., aspirin, mesalamine, azodisalicylate, salsalate, or sulfasalazine)
  • No concurrent parenteral antibiotics
  • Concurrent low-dose aspirin for cardiovascular prevention allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00039520

Layout table for location information
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
Fox Chase Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Mary Cianfrocca, DO Fox Chase Cancer Center

Layout table for additonal information
Responsible Party: Fox Chase Cancer Center Identifier: NCT00039520    
Other Study ID Numbers: CDR0000069390
P30CA006927 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: May 6, 2014
Last Verified: May 2014
Keywords provided by Fox Chase Cancer Center:
stage IV breast cancer
recurrent breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors